ArticleNature nanotechnology2020
Transformable peptide nanoparticles arrest HER2 signalling and cause cancer cell death in vivo.
Open access · greenAbstract read
In one paragraph
Article in Nature nanotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
17.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 257 citations in OpenAlex.
- Stimuli-responsive structural transformation of adaptive peptide nanomaterials toward biomedical applications.Materials today. Bio · 2026Review
- Receptor-Triggered Peptide Self-Assembly Enables Multivalent Recruitment of Endogenous Antibodies for Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Enzyme-Guided Assembly Enables Precision Delivery of a Singlet Oxygen Battery for Membrane Lipid Peroxidation Therapy.Angewandte Chemie (International ed. in English) · 2026Article
- In vivo membrane engineering traps Gd-based MRI contrast agents for detecting microhepatocellular carcinoma.Science advances · 2026Article
- Molecular rotor-based probes for protein monitoring in biomedical research.Nature reviews. Chemistry · 2026Review
- Enzyme-responsive peptide dendron nanoassemblies for targeting and eliminating intracellular drug-resistant bacteria.Nature communications · 2026Article
- Review
- Precise Regulation of Membrane Proteins: From Physical Technology to Biomolecular Strategy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Nanorobots hold PD-L1 and break membrane of colorectal cancer cells for immunotherapy.Nature nanotechnology · 2026Article
- Iron-silver-modified quantum dots act as efficient catalysts in anti-cancer multitherapy through controlled, ultrasound-induced oxidation.Nature nanotechnology · 2025Article
- Tandem-controlled lysosomal assembly of nanofibres induces pyroptosis for cancer immunotherapy.Nature nanotechnology · 2025Article
- Supramolecular peptide hydrogel epitope vaccine functionalized with CAR-T cells for the treatment of solid tumors.Materials today. Bio · 2025Article
- D-M159 Synergistically Induces Apoptosis in HeLa Cells Through Endoplasmic Reticulum Stress and Mitochondrial Dysfunction.International journal of molecular sciences · 2025Article
- Learning lessons from nano-medicine to improve the design and performances of nano-agrochemicals.Nature communications · 2025Review
- In Situ Transformable Nanoparticle Effectively Suppresses Bladder Cancer by Damaging Mitochondria and Blocking Mitochondrial Autophagy Flux.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Precision Nanomedicine for Cancer: Innovations, Strategies, and Translational Challenges.OncoTargets and therapy · 2025Review
- My Perspective on OBOC Combinatorial Technology.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Advancing gastric cancer treatment: nanotechnology innovations and future prospects.Cell biology and toxicology · 2024Review
- In situ editing of tumour cell membranes induces aggregation and capture of PD-L1 membrane proteins for enhanced cancer immunotherapy.Nature communications · 2024Article
- Enzyme-Directed and Organelle-Specific Sphere-to-Fiber Nanotransformation Enhances Photodynamic Therapy in Cancer Cells.Small methods · 2024Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Lu Zhang *Department of Biochemistry and Molecular Medicine, UC Davis NCI-designated Comprehensive Cancer Center, University of California Davis, Sacramento, CA, USA.ORCID http://orcid.org/0000-0002-7492-6047
Di Jing *Department of Biochemistry and Molecular Medicine, UC Davis NCI-designated Comprehensive Cancer Center, University of California Davis, Sacramento, CA, USA.
Nian JiangDepartment of Radiation Oncology, School of Medicine, University of California Davis, Sacramento, CA, USA.
Tatu RojalinDepartment of Biochemistry and Molecular Medicine, UC Davis NCI-designated Comprehensive Cancer Center, University of California Davis, Sacramento, CA, USA.
Christopher M BaehrDepartment of Biochemistry and Molecular Medicine, UC Davis NCI-designated Comprehensive Cancer Center, University of California Davis, Sacramento, CA, USA.
Dalin ZhangDepartment of Biochemistry and Molecular Medicine, UC Davis NCI-designated Comprehensive Cancer Center, University of California Davis, Sacramento, CA, USA.
Wenwu XiaoDepartment of Biochemistry and Molecular Medicine, UC Davis NCI-designated Comprehensive Cancer Center, University of California Davis, Sacramento, CA, USA.
Yi WuDepartment of Biochemistry and Molecular Medicine, UC Davis NCI-designated Comprehensive Cancer Center, University of California Davis, Sacramento, CA, USA.
Zhaoqing CongDepartment of Biochemistry and Molecular Medicine, UC Davis NCI-designated Comprehensive Cancer Center, University of California Davis, Sacramento, CA, USA.
Jian Jian LiDepartment of Radiation Oncology, School of Medicine, University of California Davis, Sacramento, CA, USA.ORCID http://orcid.org/0000-0003-3694-9675
Yuanpei LiDepartment of Biochemistry and Molecular Medicine, UC Davis NCI-designated Comprehensive Cancer Center, University of California Davis, Sacramento, CA, USA.ORCID http://orcid.org/0000-0002-4015-646X
Lei WangCAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Beijing, China. wanglei@nanoctr.cn.ORCID http://orcid.org/0000-0003-1405-9815
Kit S LamDepartment of Biochemistry and Molecular Medicine, UC Davis NCI-designated Comprehensive Cancer Center, University of California Davis, Sacramento, CA, USA. kslam@ucdavis.edu.ORCID http://orcid.org/0000-0002-3076-6969
University of California, Davis · USCentral South University · CNNational Center for Nanoscience and Technology · CNUniversity of California System · US
Funding
Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Gina M Dayton · 2002 to 2026
$84.9MTherapeutic Targeting Agents for Ovarian CancerR01CA115483 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI LAM, KIT S · 2005 to 2019
$5.5MTargeting nanotherapeutics against murine and feline oral cancerR01EB012569 · NIBIB · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LAM, KIT S · 2011 to 2019
$4.2MNano-Therapeutic Approaches for Oncogenic Herpesvirus-Mediated MalignanciesR01CA232845 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI IZUMIYA, YOSHIHIRO, LI, YUANPEI · 2018 to 2022
$3.2MThe rodent eye as a non-invasive window for understanding cancer nanotherapeuticsU01CA198880 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LAM, KIT S · 2015 to 2019
$2.9MStimuli-responsive crosslinked theranostics against advanced prostate cancerR01CA199668 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LI, YUANPEI · 2015 to 2019
$1.8MSmart targeting nano-theranostics for image-guided drug delivery to pediatric brain tumorsR01HD086195 · NICHD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LI, YUANPEI · 2016 to 2020
$1.6MNCI NIH HHS R01 CA115483NCI NIH HHS R01 CA199668NCI NIH HHS R01 CA232845NCI NIH HHS U01 CA198880NIBIB NIH HHS R01 EB012569NICHD NIH HHS R01 HD086195
Abstract
Human epidermal growth factor receptor 2 (HER2) is overexpressed in >20% of breast cancers. Dimerization of HER2 receptors leads to the activation of downstream signals enabling the proliferation and survival of malignant phenotypes. Owing to the high expression levels of HER2, combination therapies are currently required for the treatment of HER2
Indexed as
AnimalsAntineoplastic AgentsApoptosisBreast NeoplasmsCell Line, TumorErb-b2 Receptor Tyrosine KinasesFemaleHumansMiceNanoparticlesPeptidesSignal TransductionXenograft Model Antitumor AssaysAntineoplastic AgentsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesPeptides
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.